Skip to main content
SpringerLink
Log in

Weekly paclitaxel and S-1 combination chemotherapy for advanced gastric cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

There remains no standard first-line chemotherapeutic regimen for advanced gastric cancer (AGC). The aim of this study was to evaluate the efficacy and safety of combination regimen with weekly paclitaxel and S-1 as a firstline chemotherapy for AGC.

Methods

Forty-six patients with AGC were included in this study. Paclitaxel was administered weekly at a dose of 60 mg/m2 on days 1, 8 and 15, S-1 was administered orally twice daily at 80 mg/m2/day for 2 weeks. The regimen was repeated every four weeks.

Results

The results showed that the overall response rate was 45.7%, with 3 patients achieved complete response and 18 patients had a partial response, the disease control rate was 76.1%. The median progress free survival was 7.2 months [95% confidence interval (CI): 6.3–8.1 months] and the median overall survival was 11.6 months (95% CI: 10.6–12.6 months) after treatment with paclitaxel and S-1. Neutropenia occurred in 25 patients (54.3%) and grade 3/4 neutropenia was observed in 8 patients (17.4%), gastrointestinal reactions were the most common non-hematologic toxicities, while severe gastrointestinal toxicities were uncommon.

Conclusion

The regimen of weekly paclitaxel and S-1 demonstrated activity and acceptable toxicity for AGC as a first-line chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 1993, 72: 37–41.

    Article  PubMed  CAS  Google Scholar 

  2. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 1995, 71: 587–591.

    Article  PubMed  Google Scholar 

  3. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 1997, 8: 163–168.

    Article  PubMed  CAS  Google Scholar 

  4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277: 665–667.

    Article  PubMed  CAS  Google Scholar 

  5. Ganansia-Leymarie V, Bischoff P, Bergerat JP, et al. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents, 2003, 3: 291–306.

    Article  PubMed  CAS  Google Scholar 

  6. Murad AM, Petroianu A, Guimaraes RC, et al. A Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol, 1999, 22: 580–586.

    Article  PubMed  CAS  Google Scholar 

  7. Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cispla-tin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer, 1999, 85: 295–301.

    Article  PubMed  CAS  Google Scholar 

  8. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol, 2000, 11: 301–306.

    Article  PubMed  CAS  Google Scholar 

  9. Constenla M, Garcia-Arroyo R, Lorenzo I, et al. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric cancer, 2002, 5: 142–147.

    Article  PubMed  CAS  Google Scholar 

  10. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplain versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst, 2004, 96: 1682–1691.

    Article  PubMed  CAS  Google Scholar 

  11. Hsu Y, Sood AK, Sorosky JI. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol, 2004, 27: 14–18.

    Article  PubMed  CAS  Google Scholar 

  12. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am, 1998, 4: 269–274.

    PubMed  CAS  Google Scholar 

  13. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol, 1998, 21: 416–419.

    Article  PubMed  CAS  Google Scholar 

  14. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs, 1998, 9: 307–310.

    Article  PubMed  CAS  Google Scholar 

  15. Bokemeyer C, Lampe CS, Clemens MR, et al. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs, 1997, 8: 396–399.

    Article  PubMed  CAS  Google Scholar 

  16. Im CK, Jeung HC, Rha SY, et al. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol, 2008, 61: 315–321.

    Article  PubMed  CAS  Google Scholar 

  17. Li XD, Shen H, Jiang JT, et al. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol, 2011, 17: 1082–1087.

    Article  PubMed  CAS  Google Scholar 

  18. Park SH, Lee WK, Chung M, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 2006, 17: 225–229.

    Article  PubMed  CAS  Google Scholar 

  19. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs, 1996, 7: 548–557.

    Article  PubMed  CAS  Google Scholar 

  20. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology, 1999, 57: 202–210.

    Article  PubMed  CAS  Google Scholar 

  21. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer, 1998, 34: 1715–1720.

    Article  PubMed  CAS  Google Scholar 

  22. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology, 2000, 58: 191–197.

    Article  PubMed  CAS  Google Scholar 

  23. Boku N, Yamamoto S, Shirao K, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol, 2007, 25: LBA4513.

    Google Scholar 

  24. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol, 2008, 9: 215–221.

    Article  PubMed  CAS  Google Scholar 

  25. Köhne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology (Williston Park), 2000, 14: 22–25.

    Google Scholar 

  26. Wils J. Chemotherapy of metastatic gastric cancer. Gan To Kagaku Ryoho 2000, 27: 395–398.

    PubMed  Google Scholar 

  27. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 2006, 24: 4991–4997.

    Article  PubMed  Google Scholar 

  28. Chen YG, Yang JW, Cai XC, et al. The efficacy and toxicity of modified docetaxel, cisplatin and 5-fluorouracil combination therapy for 27 patients with advanced stage gastric adenocarcinoma. Chinese-German J Clin Oncol, 2010, 9: 396–400.

    Article  CAS  Google Scholar 

  29. Kawabata R, Fujiwara Y, Doki Y, et al. Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology, 2007, 72: 219–225.

    Article  PubMed  CAS  Google Scholar 

  30. Fujitani K, Narahara H, Takiuchi H, et al. Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer. Oncology, 2005, 69: 414–420.

    Article  PubMed  CAS  Google Scholar 

  31. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol, 1997, 15: 187–192.

    PubMed  CAS  Google Scholar 

  32. Kim R, Osaki A, Toge T. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer. Oncol Rep, 2001, 8: 1171–1176.

    PubMed  CAS  Google Scholar 

  33. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-smallcell lung cancer. J Clin Oncol, 1994, 12: 2682–2686.

    PubMed  CAS  Google Scholar 

  34. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol, 1998, 16: 301–308.

    Google Scholar 

  35. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol, 2009, 10: 1063–1069.

    Article  PubMed  CAS  Google Scholar 

  36. Ueda Y, Yamagishi H, Ichikawa D, et al. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer. Gastric Cancer, 2010, 13: 149–154.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The Affiliated Changzhou Tumor Hospital of Soochow University, Changzhou, 213001, China

    Yanzhi Bi, Dongxiang Zeng, Yizhong Dong, Guifeng Sheng, Honglei Song & Yang Ling

Authors
  1. Yanzhi Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dongxiang Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yizhong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guifeng Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Honglei Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yang Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dongxiang Zeng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bi, Y., Zeng, D., Dong, Y. et al. Weekly paclitaxel and S-1 combination chemotherapy for advanced gastric cancer. Chin. -Ger. J. Clin. Oncol. 12, 273–278 (2013). https://doi.org/10.1007/s10330-013-1145-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-013-1145-7

Key words

Search

Navigation